Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

UncleTomFlorida Apr. 14 at 2:22 PM

$ABCL Another nail in the Shorties’ coffins from Jack Prescott https://x.com/JackPrescottX/status/2044038574866083962?s=20https://x.com/JackPrescottX/status/2044038574866083962?s=20

1 · Reply

DragonAlgo Apr. 14 at 2:12 PM

🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2026-04-17 | Strike: $12.00 | Type: CALL Option Plan (premium): Entry: $0.04 Stop: $0.03 TP1: $0.05 TP2: $0.07 TP3: $0.10 🔗 https://dragonalgo.com

0 · Reply

bonecrack_benny Apr. 14 at 1:51 PM

$ABCL

0 · Reply

UncleTomFlorida Apr. 13 at 11:29 PM

$ABCL The most important article ever written about AbCellera. Shorties should run to cover after reading this. https://x.com/JackPrescottX/status/2043075871527899217?s=20

2 · Reply

tradersunion353 Apr. 13 at 8:14 PM

$ABCL Boring performance as usual.

1 · Reply

DragonAlgo Apr. 13 at 7:54 PM

🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2026-04-17 | Strike: $3.00 | Type: CALL Option Plan (premium): Entry: $0.68 Stop: $0.49 TP1: $0.88 TP2: $1.15 TP3: $1.62 Momentum tape remains active. 🔗 https://dragonalgo.com

0 · Reply

NorthShoreTrader2021 Apr. 13 at 7:26 PM

$ABCL I recently came across a YouTube video where the creator analyzed and tracked every stock that achieved a 10x return within a five-year period. The depth of the work is impressive, especially in how it breaks down the common characteristics shared by these high-performing companies. After reviewing those criteria, I believe AbCellera (ABCL) aligns closely with many of the same patterns seen in past 10x winners. The combination of its platform-driven business model, long-term partnerships, and potential operating leverage suggests it may be positioned similarly to those earlier breakout companies—particularly at its current stage. If you’re evaluating ABCL through a framework focused on asymmetric upside and multi-year compounding potential, this video provides a useful lens. Here’s the link so you can review the analysis yourself:https://www.youtube.com/watch?v=OJXZcUeRrcM

0 · Reply

NorthShoreTrader2021 Apr. 13 at 7:01 PM

$ABCL Bottom line : ABCL is the single strongest 10-bagger candidate that survived all screening filters: Investor52 criteria match (92/100), minimal dilution history (5% over 3 years), ~4.3 years of self-funding cash runway, massive short interest for squeeze mechanics (21.5% of float, 15.8 days to cover), defined binary catalysts in Q3-Q4 2026, and institutional accumulation by sophisticated biotech investors. The enterprise value of ~$500M for a platform that took $1B+ and 15 years to build, with $700M in liquidity and 19 molecules in clinic, represents a deeply asymmetric risk/reward at current levels. The primary risk remains binary clinical outcomes

1 · Reply

NorthShoreTrader2021 Apr. 13 at 5:57 PM

$ABCL

0 · Reply

8008track Apr. 13 at 4:54 PM

$ABCL I’ve been listening to old talks and they are illuminating. Back in January of 2023, they were talking about the work they were doing over the previous 3 years (since 2020) with GPCRs and ion channels and how difficult it was to build out a platform to discover and develop them. They are largely considered too difficult to work with and in some instances are thought to be impossible. They also think it’s a $100B opportunity. They now have 3 in IND enabling studies or clinical trials with more to come. If, big IF, they have cracked the GPCR and ion channels code and can actually create antibodies to adresss them, then this is a generational opportunity to get in on the ground floor. Lots of risks still but there is very meaningful upside.

0 · Reply

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Feb 24, 2026, 4:05 PM EST - 6 weeks ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 2 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 2 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 12, 2026, 9:00 AM EST - 3 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Dec 18, 2025, 9:00 AM EST - 4 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 4 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Nov 10, 2025, 9:00 AM EST - 5 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 6, 2025, 4:05 PM EST - 5 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 6 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 7 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Aug 27, 2025, 9:00 AM EDT - 8 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 4:05 PM EDT - 8 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

May 30, 2025, 1:00 PM EDT - 11 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 11 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

May 28, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results

May 1, 2024, 9:00 AM EDT - 2 years ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Apr 8, 2024, 12:05 PM EDT - 2 years ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 3, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Mar 19, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 11, 2024, 9:00 AM EDT - 2 years ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

Mar 5, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

Feb 23, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Resignation of Board Member

Feb 22, 2024, 8:15 PM EST - 2 years ago

AbCellera to Present at Upcoming Investor Conferences in March

UncleTomFlorida Apr. 14 at 2:22 PM

$ABCL Another nail in the Shorties’ coffins from Jack Prescott https://x.com/JackPrescottX/status/2044038574866083962?s=20https://x.com/JackPrescottX/status/2044038574866083962?s=20

1 · Reply

DragonAlgo Apr. 14 at 2:12 PM

0 · Reply

bonecrack_benny Apr. 14 at 1:51 PM

$ABCL

0 · Reply

UncleTomFlorida Apr. 13 at 11:29 PM

$ABCL The most important article ever written about AbCellera. Shorties should run to cover after reading this. https://x.com/JackPrescottX/status/2043075871527899217?s=20

2 · Reply

tradersunion353 Apr. 13 at 8:14 PM

$ABCL Boring performance as usual.

1 · Reply

DragonAlgo Apr. 13 at 7:54 PM

0 · Reply

NorthShoreTrader2021 Apr. 13 at 7:26 PM

0 · Reply

NorthShoreTrader2021 Apr. 13 at 7:01 PM

1 · Reply

NorthShoreTrader2021 Apr. 13 at 5:57 PM

$ABCL

0 · Reply

8008track Apr. 13 at 4:54 PM

0 · Reply

Art_BunyaaHa Apr. 13 at 4:32 PM

$ABCL

0 · Reply

tradersunion353 Apr. 13 at 3:39 PM

$ABCL POS can you hold your gains? The new base should be minimum $5 From there any news or what ever the catalyst price bump should kick in. Those who only want to see this stock at $3 so they can add for another decade.. bye bye..

1 · Reply

sogenerous Apr. 13 at 2:30 PM

$ABCL maybe can run to 4.6-5.3+ from before data

1 · Reply

DeMampCamp Apr. 13 at 2:12 PM

$ABCL The sky isn't falling! Let's get back above $4 this week!

0 · Reply

Odoji Apr. 13 at 2:00 PM

$ABCL 💉

0 · Reply

DeMampCamp Apr. 13 at 1:53 PM

$ABCL You spelled "I prematurely bought into this company and don't want to take any accountability with that" wrong! As stated endlessly, the REAL longs here aren't "happy", we just don't sit here constantly and bitch, we understand that we bought way too early and we have 2 choices 1) sell and move on 2) ride it out and with given time and success reap long term capital gains. It's almost up 2% today on a overall red market, but of course, nothing positive from you.

0 · Reply

MoneyClaw Apr. 13 at 1:50 PM

$ABCL slow and steady rise over the next few weeks!

0 · Reply

StockMacroView Apr. 13 at 7:38 AM

JonesTrading just put a megaphone to $ABCL, initiating a Buy with a massive $11.00 target—a +219% leap from current levels. While analyst Debanjana Chatterjee is swinging for the fences compared to the $7.75 consensus, the broader sentiment is undeniably green: 75% of analysts sit in the "Buy" or "Strong Buy" camps. Make no mistake, this is the classic biotech probability game. The binary risk of clinical trials remains the ultimate gatekeeper. Whether we hit $11 or $7.75 depends entirely on the data. However, $ABCL’s proprietary technology platform is the "X-factor" that tilts the odds. High risk, high tech, massive implied reward. 👉Click to view @StockMacroView for timely updates amid the volatility.

0 · Reply

DragonAlgo Apr. 11 at 9:06 PM

0 · Reply

tradersunion353 Apr. 11 at 5:40 PM

$ABCL Real talk: down 90%+ from IPO. Five consecutive years of losses. If you’re still calling this bullish— you’re not a long, you’re married to the stock. There’s a difference. Save the “biotech is volatile” speech. Volatile goes both ways. Other biotechs went UP in this window. I hold this too. every long investors deserves returns.

2 · Reply

UncleTomFlorida Apr. 11 at 2:46 PM

$ABCL $IBRX $PLTR Public Short to Float $IBRX - 39.34% https://finviz.com/quote.ashx?t=IBRX&ty=c&ta=1&p=d $ABCL - 21.69% https://finviz.com/quote.ashx?t=ABCL&ty=c&ta=1&p=d $PLTR - 2.31% (excludes options) https://finviz.com/quote.ashx?t=PLTR&ty=c&ta=1&p=d

1 · Reply

UncleTomFlorida Apr. 11 at 2:33 PM

$ABCL

0 · Reply

Market Cap	1.07B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	2,914,300
Avg Vol	3,448,652
Day's Range	N/A - N/A
Shares Out	303.16M
Stochastic %K	83%
Beta	0.85
Analysts	Strong Sell
Price Target	$9.43